文献速递前列腺癌前列腺增生与排尿功能障碍

前列腺癌治疗后开放尿直肠瘘修补术的长期患者报告结局

Long-term patient-reported outcomes of open urorectal fistula repair after prostate cancer treatment.
PubMed 文献 · BJU Int · 2026-03-13

本研究回顾性纳入2014至2024年接受开放尿直肠瘘修补术的29例男性,评估复发、再干预及患者报告结局。中位随访50个月,5年无复发生存率96%,无再干预生存率75%;患者满意度高,但部分存在中度尿失禁。

要点

  • 开放尿直肠瘘修补术5年无复发生存率达96%,无再干预生存率75%。
  • 术后排尿功能恢复,患者满意度高,决策后悔极低。
  • 部分患者持续中度尿失禁,可能反映基础疾病影响。

核心结论

  • 开放尿直肠瘘修补术可实现持久的瘘管闭合,长期结局良好,即使复杂病例亦如此。
  • 患者满意度高,但部分患者持续中度尿失禁,可能反映基础疾病。
  • 排尿功能和粪便控便基本保留。

研究设计与样本

  • 回顾性研究,纳入2014至2024年接受开放尿直肠瘘修补术的29例男性患者。
  • 收集体合并症、前列腺癌治疗史、既往尿直肠瘘干预及术中细节。
  • 终点为无复发生存、无再干预生存及经验证的患者报告结局指标。
  • 采用Kaplan-Meier法进行生存分析,患者报告结局按标准方案评分。

主要发现

  • 中位年龄68(61-71)岁,中位体重指数26(23-28)kg/m2,前列腺切除至尿直肠瘘修补中位时间10(4-13)个月。
  • 5例(17%)既往接受盆腔放疗,13例(45%)接受再次修补。
  • 症状包括直肠漏尿(48%)、气尿(24%)、反复感染(21%)、排尿困难(21%)及粪尿(10%)。
  • 经会阴修补26例(90%),经腹修补3例(10%),中位手术时间90(80-107)分钟。
  • 复发中位随访50个月,再干预中位随访58个月;5年无复发生存率96%,无任何疾病相关再干预生存率75%。

关键数值与推荐

  • 尿道狭窄手术患者报告结局中六项下尿路症状评分中位4(2-8)。
  • 国际尿失禁咨询问卷-尿失禁简表总分中位11(6-15)。
  • Wexner粪便失禁评分中位3(1-9)。
  • 国际尿失禁咨询问卷-满意度结局评分中位21(18-23)。
  • 决策后悔量表评分中位0(0-10)。

临床怎么用

  • 开放尿直肠瘘修补术可作为前列腺癌治疗后尿直肠瘘的有效选择,尤其复杂病例。
  • 术前应告知患者部分可能持续中度尿失禁,但排尿和控便功能多保留,满意度高。

局限性

  • 回顾性研究,样本量较小(29例)。
  • 单中心经验,结果可能受选择偏倚影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate long-term outcomes of open urorectal fistula (URF) repair, including URF recurrence, need for re-intervention, and patient-reported outcomes. PATIENTS AND METHODS: This retrospective study included men undergoing open URF repair between 2014 and 2024. Data collected encompassed comorbidities, prostate cancer treatment history, prior URF interventions, and intraoperative details. Endpoints were: (i) URF recurrence-free survival, (ii) re-intervention-free survival (no further disease-related procedures), and (iii) validated patient-reported outcome measures (PROMs). Kaplan-Meier estimators were used for survival analyses; PROMs were scored according to standard protocols. RESULTS: A total of 29 patients underwent open URF repair. The median (interquartile range [IQR]) age was 68 (61-71) years, body mass index was 26 (23-28) kg/m2, and the time from prostatectomy to URF repair was 10 (4-13) months. Five patients (17%) had prior pelvic radiotherapy; 13 (45%) underwent redo repairs. Presenting symptoms included rectal urine leakage (48%), pneumaturia (24%), recurrent infections (21%), dysuria (21%), and faecaluria (10%). Transperineal repair was performed in 26 patients (90%) and transabdominal repair in three (10%). The median (IQR) operating time was 90 (80-107) min. The median follow-up was 50 months for recurrence and 58 months for re-intervention. The 5-year URF recurrence-free and any disease-related re-intervention-free survival estimates were 96% and 75%, respectively. The median (IQR) six-item lower urinary tract symptoms score from the Urethral Stricture Surgery PROM was 4 (2-8), International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form sum score was 11 (6-15), Wexner faecal incontinence score was 3 (1-9), International Consultation on Incontinence Questionnaire-Satisfaction outcome score was 21 (18-23), and Decision Regret Scale score was 0 (0-10), indicating restored voiding function, moderate urinary incontinence, mild faecal incontinence, high patient satisfaction, and negligible decisional regret. CONCLUSION: Open URF repair achieves durable URF closure with favourable long-term outcomes, even in complex cases. Patient satisfaction is high, while moderate urinary incontinence persists in some, likely reflecting underlying disease. Voiding and faecal continence remain largely preserved.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Wagner MC, Klemm J, Roessler N, et al. Long-term patient-reported outcomes of open urorectal fistula repair after prostate cancer treatment. BJU Int. 2026. PMID: 41826795. doi:10.1111/bju.70233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。